# Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

> **NCT07226661** · PHASE2 · RECRUITING · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 230 (estimated)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** SPN-821 2400 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07226661
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-19
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07226661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07226661, "Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07226661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*